Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xencor Set To Spruce Up Pfizer Antibodies

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer gains wide access to test-drive antibody-enhancing tools via new licensing deal.
Advertisement

Related Content

J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
Deals Of The Week: Merck Serono/Ambrx, Actelion/GeneraMedix...
Deals Of The Week: Merck Serono/Ambrx, Actelion/GeneraMedix...
Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal
Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Genentech Takes Over GlycArt Anti-CD20 Antibody Work

Topics

Advertisement
UsernamePublicRestriction

Register

PS069155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel